C-FBJIMuna Therapeutics
small molecules, microglia, resilience
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FBJI
C-FBJIC-FBJIsmall molecules, microglia, resilience
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Muna Therapeutics small molecules, microglia, resilience
Muna Therapeutics discovers and develops therapies intended to slow or stop neurodegenerative diseases including Alzheimer’s and Parkinson’s. The company focuses on preserving cognition and other brain functions, enhancing resilience to disease pathology, and resolving neuroinflammation. Its all-in-human MiND-MAP discovery and validation approach uses single-cell spatial multi-omics, bioinformatics, structural biology, computational chemistry, and cell-based screening.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Muna Therapeutics — Translational · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic